Superworth

Greenwich LifeSciences EPS GLSI

Diluted earnings per share by quarter and over the last twelve months, from 2019.

Last 12 months, to Jun 30, 2026
−$1.59
Latest quarter, Q2 FY26
−$0.27
Fiscal year 2025
−$1.42

Greenwich LifeSciences' earnings per share was −$1.59 over the twelve months to Jun 30, 2026.

In its latest quarter, Q2 FY26, it was −$0.27.

Earnings per share over time

Open the interactive chart, with overlays and comparisons

Fiscal year by fiscal year

Fiscal yearEPSChange
FY2025−$1.42n/a
FY2024−$1.20n/a
FY2023−$0.70n/a
FY2022n/an/a
FY2021−$0.36n/a
FY2020−$0.18n/a

Each fiscal year is the twelve months to its fourth quarter.

Quarter by quarter

QuarterEndedEPSOn a year earlierLast 12 months
Q2 FY26−$0.27n/a−$1.59
Q1 FY26−$0.39n/a−$1.60
Q4 FY25−$0.66n/a−$1.42
Q3 FY25−$0.27n/a−$1.37
Q2 FY25−$0.28n/a−$1.30
Q1 FY25−$0.21n/a−$1.22
Q4 FY24−$0.61n/a−$1.20
Q3 FY24−$0.20n/a−$0.80
Q2 FY24−$0.20n/a−$0.79
Q1 FY24−$0.19n/a−$0.72
Q4 FY23−$0.21n/a−$0.70
Q3 FY23−$0.19n/a−$0.71

Against its peers

Companies in Drug Manufacturers - General nearest Greenwich LifeSciences' size, closest first, today.

CompanyEPS, 12 monthsGrowth
GLSIGreenwich LifeSciences−$1.59
NATRNatures Sunshine Products$1.01+36% a year
ARVNArvinas$0.16
PBYIPuma Biotechnology$0.52−47% a year
IRWDIronwood Pharmaceuticals$0.77
ZVRAZevra Therapeutics$0.93
CRMDCorMedix$2.13+184% a year
COLLCollegium Pharmaceutical$1.24+19% a year
LFVNLifevantage$0.40−46% a year
ABUSArbutus Biopharma$0.78
SPROSpero Therapeutics$0.11
Peer median$0.78

What the EPS figure tells you

Net income divided by diluted shares. The denominator of PE.

One-off charges and gains swing it. The TTM view smooths a single odd quarter.

More on Greenwich LifeSciences

Valuation data, not investment advice. Prices as of . Reported figures come from the company's filings with the SEC.